110 related articles for article (PubMed ID: 22753836)
1. EGFR and K-ras mutations in cytologic samples from fine-needle aspirates in NSCLC patients.
Ulivi P; Zoli W; Chiadini E; Capelli L; Candoli P; Calistri D; Silvestrini R; Puccetti M
Eur Respir J; 2012 Jul; 40(1):267-9. PubMed ID: 22753836
[No Abstract] [Full Text] [Related]
2. [Detection of EGFR and K-ras mutations in non-small cell lung cancer using cytological specimens].
Lu SS; Xu X; Guo HQ; Cao J; Pan QJ; Wang MR
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):585-9. PubMed ID: 24314215
[TBL] [Abstract][Full Text] [Related]
3. Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer.
Lozano MD; Labiano T; Echeveste J; Gurpide A; Martín-Algarra S; Zhang G; Sharma A; Palma JF
Cancer Cytopathol; 2015 Apr; 123(4):230-6. PubMed ID: 25529460
[TBL] [Abstract][Full Text] [Related]
4. Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients.
Ulivi P; Romagnoli M; Chiadini E; Casoni GL; Capelli L; Gurioli C; Zoli W; Saragoni L; Dubini A; Tesei A; Amadori D; Poletti V
Int J Oncol; 2012 Jul; 41(1):147-52. PubMed ID: 22504767
[TBL] [Abstract][Full Text] [Related]
5. Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer.
Bozzetti C; Naldi N; Nizzoli R; Azzoni C; Bortesi B; Zobbi V; Bottarelli L; Tiseo M; Gasparro D; Majori M; De Filippo M; Ardizzoni A
Lung Cancer; 2013 Apr; 80(1):35-8. PubMed ID: 23352033
[TBL] [Abstract][Full Text] [Related]
6. A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates.
Schuurbiers OC; Looijen-Salamon MG; Ligtenberg MJ; van der Heijden HF
J Thorac Oncol; 2010 Oct; 5(10):1664-7. PubMed ID: 20871266
[TBL] [Abstract][Full Text] [Related]
7. [Clinical Research of EGFR and KRAS Mutation in Fine Needle Aspiration Cytology Specimens of Non-small Cell Lung Carcinoma].
Zhang Z; Wu X; Ying J; Li J; Qiu T; Guo H; Zhao H; Shan L; Ling Y
Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):199-205. PubMed ID: 25936883
[TBL] [Abstract][Full Text] [Related]
8. Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis.
Fassina A; Gazziero A; Zardo D; Corradin M; Aldighieri E; Rossi GP
J Clin Pathol; 2009 Dec; 62(12):1096-102. PubMed ID: 19640859
[TBL] [Abstract][Full Text] [Related]
9. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens.
Billah S; Stewart J; Staerkel G; Chen S; Gong Y; Guo M
Cancer Cytopathol; 2011 Apr; 119(2):111-7. PubMed ID: 21400670
[TBL] [Abstract][Full Text] [Related]
10. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
[TBL] [Abstract][Full Text] [Related]
11. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
12. Molecular alterations in non-small cell lung carcinomas of the young.
VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
[TBL] [Abstract][Full Text] [Related]
13. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status.
Kalikaki A; Koutsopoulos A; Hatzidaki D; Trypaki M; Kontopodis E; Stathopoulos E; Mavroudis D; Georgoulias V; Voutsina A
Lung Cancer; 2010 Jul; 69(1):110-5. PubMed ID: 19854533
[TBL] [Abstract][Full Text] [Related]
15. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.
Ragusa M; Vannucci J; Ludovini V; Bianconi F; Treggiari S; Tofanetti FR; Flacco A; Colella R; Sidoni A; Crinò L; Puma F
Am J Clin Oncol; 2014 Aug; 37(4):343-9. PubMed ID: 23357969
[TBL] [Abstract][Full Text] [Related]
16. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
[TBL] [Abstract][Full Text] [Related]
17. Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology.
Zhang H; Liu D; Li S; Zheng Y; Yang X; Li X; Zhang Q; Qin N; Lu J; Ren-Heidenreich L; Yang H; Wu Y; Zhang X; Nong J; Sun Y; Zhang S
J Mol Diagn; 2013 Nov; 15(6):819-26. PubMed ID: 23988622
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
[TBL] [Abstract][Full Text] [Related]
19. Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).
Beau-Faller M; Degeorges A; Rolland E; Mounawar M; Antoine M; Poulot V; Mauguen A; Barbu V; Coulet F; Prétet JL; Bièche I; Blons H; Boyer JC; Buisine MP; de Fraipont F; Lizard S; Olschwang S; Saulnier P; Prunier-Mirebeau D; Richard N; Danel C; Brambilla E; Chouaid C; Zalcman G; Hainaut P; Michiels S; Cadranel J
J Thorac Oncol; 2011 Jun; 6(6):1006-15. PubMed ID: 21532509
[TBL] [Abstract][Full Text] [Related]
20. Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy.
Yamaguchi F; Kugawa S; Tateno H; Kokubu F; Fukuchi K
Lung Cancer; 2012 Dec; 78(3):201-6. PubMed ID: 23026641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
